Mollugin

Research use only, not for human use.

Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway.

Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.

Rubimaillin; Mollugin

Chromatin/Epigenetic

COX

HER2; JAK2

Others-Field

——

55481-88-4

284.3

C17H16O4

98%

——

CC1(C=Cc2c(O1)c1ccccc1c(c2C(=O)OC)O)C

methyl 6-hydroxy-2,2-dimethyl-2H-benzo[h]chromene-5-carboxylate

(-20℃)

With Ice Pack

≥ 2 years